{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06444529",
            "orgStudyIdInfo": {
                "id": "DEW422-C001"
            },
            "organization": {
                "fullName": "Alcon Research",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness",
            "officialTitle": "A Double-Masked Comparison of Apraclonidine Hydrochloride Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness",
            "therapeuticArea": [
                "Ophthalmology"
            ],
            "study": "a-double-masked-comparison-of-fid-ophthalmic-solution-to-vehicle-for-the-reduction-of-ocular-redness"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-31",
            "studyFirstSubmitQcDate": "2024-05-31",
            "studyFirstPostDateStruct": {
                "date": "2024-06-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-31",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Alcon Research",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to assess the safety and efficacy of Apraclonidine Hydrochloride Ophthalmic Solution 0.125% when compared to Vehicle, in relieving redness of the eye due to minor eye irritations. This study will be conducted in the United States.",
            "detailedDescription": "The study will consist of six (6) scheduled visits: Screening and/or Baseline Visit (Day -7 to -1), Eligibility Confirmation/Randomization/1st Treatment Visit (Day 1), Week 2 Follow-Up Visit (Day 14), Week 4 Follow-Up Visit (Day 28), Week 8 Follow-Up/Treatment Discontinuation Visit (Day 56) and Exit Visit (Day 63). The expected individual duration of participation in the study is approximately 10 weeks with approximately 56 days of exposure to the investigational product."
        },
        "conditionsModule": {
            "conditions": [
                "Ocular Redness"
            ],
            "keywords": [
                "Eye redness",
                "Irritated eyes"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 240,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Apraclonidine Hydrochloride Ophthalmic Solution",
                    "type": "EXPERIMENTAL",
                    "description": "One drop in each eye on Day 1, followed by 2 drops in each eye on Day 2 onward for approximately 8 weeks",
                    "interventionNames": [
                        "Drug: Apraclonidine Hydrochloride Ophthalmic Solution"
                    ]
                },
                {
                    "label": "Vehicle",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "One drop in each eye on Day 1, followed by 2 drops in each eye on Day 2 onward for approximately 8 weeks",
                    "interventionNames": [
                        "Drug: Vehicle"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Apraclonidine Hydrochloride Ophthalmic Solution",
                    "description": "Investigational ophthalmic solution applied topically to the eye with a dropper bottle",
                    "armGroupLabels": [
                        "Apraclonidine Hydrochloride Ophthalmic Solution"
                    ],
                    "otherNames": [
                        "FID 123320"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Vehicle",
                    "description": "Vehicle (inactive ingredients) applied topically to the eye with a dropper bottle",
                    "armGroupLabels": [
                        "Vehicle"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Mean change from baseline in investigator-assessed ocular redness at 15 minutes post-instillation on Day 1",
                    "description": "Ocular redness will be assessed by the investigator using a scale from 0 to 4 in half-unit increments (0=none; 4=extremely severe). This endpoint is co-primary with the 10 hours post-instillation endpoint.",
                    "timeFrame": "Day 1: Pretreatment; 15 minutes post-treatment"
                },
                {
                    "measure": "Mean change from baseline in investigator-assessed ocular redness at 10 hours (600 minutes) post-instillation on Day 1",
                    "description": "Ocular redness will be assessed by the investigator using a scale from 0 to 4 in half-unit increments (0=none; 4=extremely severe). This endpoint is co-primary with the 15 minutes post-instillation endpoint.",
                    "timeFrame": "Day 1: Pretreatment; 10 hours (600 minutes) post-treatment"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Mean change from baseline in investigator-assessed ocular redness at 1 minute post-instillation on Day 1",
                    "description": "Ocular redness will be assessed by the investigator using a scale from 0 to 4 in half-unit increments (0=none; 4=extremely severe).",
                    "timeFrame": "Day 1: Pretreatment; 1 minute post-treatment"
                },
                {
                    "measure": "Mean change from baseline in investigator-assessed ocular redness at 8 hours (480 minutes) post-instillation on Day 1",
                    "description": "Ocular redness will be assessed by the investigator using a scale from 0 to 4 in half-unit increments (0=none; 4=extremely severe).",
                    "timeFrame": "Day 1: Pretreatment; 8 hours (480 minutes) post-treatment"
                },
                {
                    "measure": "Mean change from baseline in investigator-assessed ocular redness at 12 hours (720 minutes) post-instillation on Day 1",
                    "description": "Ocular redness will be assessed by the investigator using a scale from 0 to 4 in half-unit increments (0=none; 4=extremely severe).",
                    "timeFrame": "Day 1: Pretreatment; 12 hours (720 minutes) post-treatment"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Capable of giving signed informed consent;\n* Willing and able to follow all instructions and attend all study visits;\n* Able to self-administer eye drops- in the opinion of the investigator;\n* History of redness relief drop use within the last 6 months, or a desire to use over-the-counter (OTC) eye drops for redness relief;\n* Females capable of becoming pregnant: Agree to urine pregnancy tests and the use of medically acceptable forms of birth control throughout the study;\n* Ocular health within normal limits, including best-corrected visual acuity (BCVA) of 20/40 or better in each eye as measured using a Snellen chart;\n* Ocular redness at baseline as specified in the protocol;\n* Other protocol-specified inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Known contraindications or sensitivities to the use of any of the investigational drug(s) or their components, or any other medication required by the protocol;\n* Ocular surgical interventions within 6 months prior to Visit 1 or during the study;\n* Ocular conditions that, in the opinion of the investigator, could affect the subject's safety or study parameters (i.e., could affect ocular redness, intraocular pressure, or eyelid position);\n* Disallowed medications or devices as specified in the protocol;\n* Planned surgery (ocular or systemic) during the study period or within 30 days after the study period;\n* Other protocol-defined exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Alcon Call Center",
                    "role": "CONTACT",
                    "phone": "1-888-451-3937",
                    "email": "alcon.medinfo@alcon.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Principal Clinical Trial Lead, Pharma",
                    "affiliation": "Alcon Research, LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Contact Alcon Call Center for Trial Locations",
                    "city": "Fort Worth",
                    "state": "Texas",
                    "zip": "76134",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.72541,
                        "lon": -97.32085
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000004890",
                    "term": "Erythema"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000012877",
                    "term": "Skin Manifestations"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M8044",
                    "name": "Erythema",
                    "asFound": "Redness",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15680",
                    "name": "Skin Manifestations",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009883",
                    "term": "Ophthalmic Solutions"
                },
                {
                    "id": "C000016986",
                    "term": "Apraclonidine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019999",
                    "term": "Pharmaceutical Solutions"
                },
                {
                    "id": "D000058647",
                    "term": "Adrenergic alpha-2 Receptor Agonists"
                },
                {
                    "id": "D000000316",
                    "term": "Adrenergic alpha-Agonists"
                },
                {
                    "id": "D000000322",
                    "term": "Adrenergic Agonists"
                },
                {
                    "id": "D000018663",
                    "term": "Adrenergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M12814",
                    "name": "Ophthalmic Solutions",
                    "asFound": "Anxiety",
                    "relevance": "HIGH"
                },
                {
                    "id": "M230201",
                    "name": "Apraclonidine",
                    "asFound": "Psychiatric Unit",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20746",
                    "name": "Adrenergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M3668",
                    "name": "Adrenergic alpha-Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M3673",
                    "name": "Adrenergic Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}